AUGTYRO
Total Payments
$136,109
Transactions
1,052
Doctors
751
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $134,039 | 926 | 648 |
| 2023 | $2,070 | 126 | 114 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $97,520 | 23 | 71.6% |
| Food and Beverage | $21,731 | 987 | 16.0% |
| Travel and Lodging | $14,357 | 40 | 10.5% |
| Consulting Fee | $2,500 | 2 | 1.8% |
Ad
Manufacturing Companies
- E.R. Squibb & Sons, L.L.C. $136,072
- Celgene Corporation $36.30
Product Information
- Type Drug
- Total Payments $136,109
- Total Doctors 751
- Transactions 1,052
About AUGTYRO
AUGTYRO is a drug associated with $136,109 in payments to 751 healthcare providers, recorded across 1,052 transactions in the CMS Open Payments database. The primary manufacturer is E.R. Squibb & Sons, L.L.C..
Payment data is available from 2023 to 2024. In 2024, $134,039 was paid across 926 transactions to 648 doctors.
The most common payment nature for AUGTYRO is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($97,520, 71.6% of total).